Ovarian cancer
Results
Phase 3
This trial looked at carboplatin, gemcitabine, bevacizumab and pegylated liposomal doxorubicin to treat recurrent ovarian cancer.
It was for women whose ovarian cancer came back (recurred) more than 6 months after initially responding to platinum chemotherapy drugs.
The trial was for women who have:
These cancers are treated in the same way, so when we use the term ovarian cancer in this summary, we are referring to all of these.
This trial was open in the UK for women to join between January 2015 and August 2015. These results were presented at a conference in 2019.
Recruitment start: 20 January 2015
Recruitment end: 6 August 2015
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Ros Glasspool
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
Roche
NHS Greater Glasgow and Clyde
AGO study group
This is Cancer Research UK trial number CRUKE/13/027.
Last reviewed: 5 February 2020
CRUK internal database number: 11765
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
